Angela Dalia Ricci

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 12

Top Topics

Systematic Review

Ejection Fraction

Top Venues

Current oncology (Toronto, Ont.)

Journal of personalized medicine

Cancer communications (London, England)

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Alessandro Rizzo, Angela Dalia Ricci, Annarita Fanizzi, Raffaella Massafra, Raffaele De Luca, Giovanni Brandi
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current oncology (Toronto, Ont.) 30 (1) (2023)
Alessandro Rizzo, Angela Dalia Ricci, Annarita Fanizzi, Raffaella Massafra, Raffaele De Luca, Giovanni Brandi
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current oncology (Toronto, Ont.) 30 (1) (2023)
Alessandro Rizzo, Angela Dalia Ricci, Annarita Fanizzi, Raffaella Massafra, Raffaele De Luca, Giovanni Brandi
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current oncology (Toronto, Ont.) 30 (1) (2023)
Alessandro Rizzo, Angela Dalia Ricci, Annarita Fanizzi, Raffaella Massafra, Raffaele De Luca, Giovanni Brandi
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current oncology (Toronto, Ont.) 30 (1) (2023)
Alessandro Rizzo, Angela Dalia Ricci, Annarita Fanizzi, Raffaella Massafra, Raffaele De Luca, Giovanni Brandi
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current oncology (Toronto, Ont.) 30 (1) (2023)
Alessandro Rizzo, Angela Dalia Ricci, Annarita Fanizzi, Raffaella Massafra, Raffaele De Luca, Giovanni Brandi
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis. Current oncology (Toronto, Ont.) 30 (1) (2023)
Alessandro Rizzo, Angela Dalia Ricci
Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy. International journal of molecular sciences 23 (19) (2022)
Alessandro Rizzo, Massimiliano Salati, Giorgio Frega, Valeria Merz, Francesco Caputo, Alessandro Di Federico, Andrea Palloni, Riccardo Carloni, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola, Carlo Messina, Andrea Spallanzani, Fabio Gelsomino, Stefania Benatti, Gabriele Luppi, Davide Melisi, Massimo Dominici, Giovanni Brandi
Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study. Medicina (Kaunas, Lithuania) 58 (11) (2022)
Alessandro Rizzo, Riccardo Carloni, Angela Dalia Ricci, Alessandro Di Federico, Deniz Can Guven, Suayib Yalcin, Giovanni Brandi
Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis. Journal of personalized medicine 12 (8) (2022)
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. Journal of personalized medicine 12 (11) (2022)
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. Journal of personalized medicine 12 (11) (2022)
Giovanni Brandi, Angela Dalia Ricci, Alessandro Rizzo, Chiara Zanfi, Simona Tavolari, Andrea Palloni, Stefania De Lorenzo, Matteo Ravaioli, Matteo Cescon
Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases? Cancer communications (London, England) 40 (9) (2020)